Nano Holdings.Inc.
0.45
EUR
+0.02
(+3.70%)
ISIN
JP3651120002
Return %
Stock
S&P 500
1Y
-52.09
14.20
3Y
-61.38
81.12
5Y
-80.35
68.34
Capital Structure
JPY
•
in mil. unless spec.Working Capital
JPY
•
in mil. unless spec.Growth Rates
JPY
•
in mil. unless spec.Quarterly Revenue
JPY
•
in mil. unless spec.Quarterly Earnings Per Share
JPY
•
in mil. unless spec.Quarterly Dividends Per Share
JPY
•
in mil. unless spec.Company Description
- CEO
- Atsushi Matsumura
- Full Time Employees
- 23
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- 2-5-1 Atago, Atago Green Hills Mori Tower 26F Tokyo Japan 105-6226
- IPO Date
- Mar 5, 2008
- Website
- nanomrna.co.jp
- Similar Companies
- Business
- NANO MRNA Co.,Ltd. conducts research, development, production, and sales of pharmaceuticals with a focus on mRNA therapeutics and drug delivery systems based on proprietary micellar nanoparticle technology. Its core products and services include mRNA drug discovery and development platform operations; pipeline products such as RUNX1 mRNA for osteoarthritis tissue regeneration; TUG1 antisense oligonucleotide (ASO) for glioblastoma multiforme in Phase 1 clinical trials; NC-6100 PRDM14 siRNA in early-stage development for breast cancer; and antibacterial otic solution Complex®, co-developed with Ceoria Pharma and launched in 2023. The company also provides cosmetics raw materials and platelet-rich therapies. Headquartered in Minato-ku, Tokyo, and founded as NanoCarrier in 2004, it rebranded to NANO MRNA in June 2023 to emphasize its shift toward mRNA therapeutics and intellectual property (IP) generation as a platformer connecting drug discovery seeds with medical and pharmaceutical development needs. In recent strategic developments, NANO MRNA formed a strategic alliance with SBI Securities and SBI Shinsei Corporate Investment to pioneer a "Healthcare Conglomerate" business model that integrates bio-healthcare expertise with financial and investment capabilities. Effective April 2026, NANO MRNA plans to transition to a holding company structure and enter the financial services sector, establishing an investment subsidiary, Nano Bridge Investment, to jointly operate funds targeting transformative healthcare technologies including RNA therapeutics, regenerative medicine, AI-driven drug discovery, and novel drug delivery systems. The company has also recently secured funding from SBI Securities and continues advancing its clinical programs, including initiating Phase 1 clinical trials for RUNX1 mRNA targeting knee osteoarthritis. This strategic shift broadens NANO MRNA's business from solely pharmaceutical R&D into integrated healthcare investment and ecosystem development, aiming to maximize corporate and pipeline value through strategic partnerships and equity investments primarily in Japan and globally expanding markets. The company maintains ongoing collaborations with Kao Corporation and Senju Pharmaceutical in therapeutic vaccine and ophthalmology research, respectively, emphasizing its pipeline-centric, nonclinical stage business model. NANO MRNA operates primarily in the biotechnology and pharmaceutical industry within Japan and internationally, focusing on drug discovery, development, and licensing of mRNA and RNA-based therapies. Its evolving business model as a platform company for mRNA medicine IP creation, out-licensing, and capital market integration characterizes it as a pioneer in Japan's bio-venture ecosystem with a commitment to innovation and sustainable growth.